Anifrolumab (blinded)

COMBINATION_PRODUCT2 trials

Sponsors

AstraZeneca

Conditions

Polymyositis, DermatomyositisSclerodermaSystemic Sclerosis

Phase 3

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Active, not recruitingNCT05925803

AstraZenecaScleroderma, Systemic Sclerosis

Start: 2023-11-08End: 2028-04-05Updated: 2026-09-10

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

RecruitingNCT06455449

AstraZenecaPolymyositis, Dermatomyositis

Start: 2024-06-20End: 2028-08-04Target: 240Updated: 2026-05-28

Related Papers

Anifrolumab in Refractory Dermatomyositis and Antisynthetase Syndrome

Case Reports in Rheumatology2025-01-012 citations